Navigation Links
Callisto Pharmaceuticals Announces Publication of Research Article,on Atiprimod Preclinical Studies in Mantle Cell Lymphoma

Article Published in Recent Issue of Journal Blood

NEW YORK, April 11, 2007 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (FWB: CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced today the publication of a research article on Atiprimod, Callisto's drug currently in clinical trials in carcinoid cancer and multiple myeloma patients, in the February 2007 issue of Blood, a peer-reviewed scientific journal that publishes original research articles related to hematological malignancies.

The article authored by Dr. Michael Wang and Dr. Qing Yi, from the University of Texas M.D. Anderson Cancer Center, focuses on Atiprimod's ability to inhibit proliferation of mantle cell lymphoma (MCL) cells in vitro and to inhibit growth of MCL tumors in tumor-bearing mice. The animal data demonstrated that Atiprimod significantly inhibited tumor growth in vivo and prolonged survival of tumor-bearing mice. Atiprimod was shown to enhance release of apoptosis-inducing factor (AIF) from cellular mitochondria, and the authors suggest that this is the mechanism of Atiprimod's apoptotic (programmed cellular death) activity.

Atiprimod is an orally bio-available small molecule drug that displays multiple mechanisms of action. The drug has been shown to be antiangiogenic, inhibit secretion of VEGF and IL-6, elicit an apoptotic response (programmed cellular death), and inhibit phosphorylation of key kinases involved in tumor progression and survival including Akt and STAT3. The drug is presently in two clinical trials: a Phase II trial in advanced carcinoid cancer patients, and a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients.

The publication appeared in Blood First Edition Paper, prepublished online February 22, 2007 DOI 10.1182/Blood-2006-12-063958 and is titled: "Atiprimod inhibits the growth of mantle cell lymph
'"/>




Page: 1 2 3

Related medicine technology :

1. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies

Post Your Comments:
(Date:11/29/2009)...wswire/ -- Stimulated by the ten years of Synapse&...Systems USA announced today, at the Radiological S... formation of its Medical Informatics Division . ...p will integrate all functions associated with the...form for future growth. ,, Several organization...
(Date:11/27/2009).... 27 Booth - 3646/South ... ), a premier supplier of X-ray tubes and flat pan...range of detectors at the RSNA Annual Meeting in C... Varian will also be exhibiting X-ray tube technol... cancer treatment technologies. ,, Varian,s ex...
(Date:11/25/2009)...v. 25 American Scientifi...") is pleased to announce that they have opened a ...e in Shanghai, China. ,, ASR has been able to s...teway for the development and production of curren...en and adults to be distributed and sold globally....
Breaking Medicine Technology:FUJIFILM Establishes Medical Informatics Organization 2FUJIFILM Establishes Medical Informatics Organization 3Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago 2American Scientific Resources Inc. Opens Shanghai Location 2Virtual maps for the blind 56801 1Virtual maps for the blind 56801 2Virtual maps for the blind 56801 3Superscanner helps scientists see into the unknown 9873 1Superscanner helps scientists see into the unknown 9873 2Superscanner helps scientists see into the unknown 9873 3Size of fat cells and waist size predict type 2 diabetes in women 9869 1Size of fat cells and waist size predict type 2 diabetes in women 9869 2
... ANTONY, France, January 19 Stallergenes S.A.,...he German agency in charge,of regulating biologica...iatric extension (5-17 years) of the indications f...sitization to grass pollens. , The marketing a...08.,Oralair(R) Grasses will therefore be marketed ...
... WILMINGTON, N.C., Jan. 19 Intercell AG has re...heir Phase III clinical trial of a,Travelers, Diar...e form of a,skin patch -- a novel method for deliv...use it is needle-free. , This year, approximat...countries where bacteria that cause TD are endemic...
Other Medicine Technology:STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany 2STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany 3STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany 4Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers' Diarrhea Vaccine Study 2Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers' Diarrhea Vaccine Study 3
(Date:11/28/2009)...er change after 30-minute psychosocial interventio...thDay News) -- A program that gets persistent drun...angerous behavior may lead to significant and long... new study included 184 men and women with two or ...randomly assigned to one of two interventions. The...
(Date:11/27/2009)...ikins Ltd. today issued its latest biochemical ana...at the lethality of the virus has dropped from its... outbreak in the spring of 2009 to resting non-epi... infectivity count, however, remains increased. ,...7, 2009 -- Biotech firm Replikins Ltd., which has ...
(Date:11/27/2009)... Shamir Optical Industry ...ider of innovative products and technology to the ...oard of directors had declared a dividend distribu...roximately NIS 37.62 million based on the November...roximately US$ 0.609 (approximately NIS 2.3 based ...
(Date:11/27/2009)...de; announced today that Spectrum Health (Grand Ra...ise orthopedic templating solution and its TraumaC... (PRWEB) November 27, 2009 -- Voyant Health&t...Rapids, Michigan) has licensed its TraumaCad Enter...aCad Extend workflow solution, to allow its orthop...
(Date:11/26/2009)...ewswire/ -- The diabetes population in the United ...nd annual medical spending on the disease is proje...ay, according to a study published in the December... Diabetes ® Program (NCDP), a program of Novo... the University of Chicago. ,, According to the...
Breaking Medicine News(10 mins):Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4
...ling certain errors in gene expression as a safer ...gs has won for Prof. Hermona Soreq, dean of the Fa...alem, one of this year,s Kaye Innovation Awards. ,...ard. , The concept behind Prof. Soreq,s work lies...
...ce function at leading contrac...e 26 /PRNewswire-FirstCall/ - MDS Pharma,Services,...nd development,solutions, has hired Dr. Lori McDon...mpliance systems across its,global business platfo...
...election,of healthcare industry veteran Mary P. Br...dent of Business Development. An experienced leade...ervice management, Ms.,Bryngelson will focus on st... to support corporate growth, business,goals, and ...
...q: CYNO ), a leading developer and manufacturer o... systems, today announced that President and,Chief...t & Young,Entrepreneur Of The Year(R) 2008 Award i...ng entrepreneurs who are building and,leading dyna...
...eloper of,novel spine arthroplasty alternatives to...ed European clinical activities on its TOPS(TM) Sy...ed to treat spinal stenosis with,or without facet ...(Logo: http://www.newscom.com/cgi-bin/prnh/200805...
...Quick to Implement, ROCKLIN, Calif., June 25 GoA... and wireless communications and,professional inte...eech-disabled persons, and AT&T today announced th...sued yesterday., The demonstration, to occur at t...
Other Medicine News:Health News:RNA engineering to combat series of illnesses wins Kaye Award for Hebrew University dean 2Health News:RNA engineering to combat series of illnesses wins Kaye Award for Hebrew University dean 3Health News:MDS Pharma Services Names Dr. Lori McDonald to Executive Leadership Team 2Health News:ACM Adds Top Industry Executive to Its Leadership Team 2Health News:Cynosure President and CEO Michael Davin Named Ernst & Young Entrepreneur of the Year(R) 2008 Award Winner in New England 2Health News:Impliant Restarts European Clinical Activities for Patented TOPS(TM) Spine System 2Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 2Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 3Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 4Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 5
CareDrape® Cardiac Blanket (Sterile)
COCOON Disposable Cardiac Access
Bair Hugger® Model 630 - Cardiac Blanket
Bair Hugger® Model 635 - Full Access Underbody Blanket
Medicine Products: